scispace - formally typeset
B

Brett A. Chromy

Researcher at University of California, Davis

Publications -  60
Citations -  8144

Brett A. Chromy is an academic researcher from University of California, Davis. The author has contributed to research in topics: Proteomics & Yersinia pestis. The author has an hindex of 34, co-authored 60 publications receiving 7666 citations. Previous affiliations of Brett A. Chromy include Northwestern University & Lawrence Livermore National Laboratory.

Papers
More filters
Journal ArticleDOI

Diffusible, nonfibrillar ligands derived from Aβ1–42 are potent central nervous system neurotoxins

TL;DR: It is hypothesized that impaired synaptic plasticity and associated memory dysfunction during early stage Alzheimer's disease and severe cellular degeneration and dementia during end stage could be caused by the biphasic impact of Abeta-derived diffusible ligands acting upon particular neural signal transduction pathways.
Journal ArticleDOI

Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus

TL;DR: The data suggest that soluble non-fibrillar amyloid may contribute to the pathogenesis of AD both by impairing LTP/memory formation at the cellular level and by creating 'neuroplasticity imbalance' manifested by unopposed LTD in the setting of impaired capacity for neural repair via reversal of LTD or LTP.
Journal ArticleDOI

Self-assembly of Aβ1-42 into globular neurotoxins

TL;DR: Aβ 1−42 (Aβ1-42) is a self-associating peptide that becomes neurotoxic upon aggregation as discussed by the authors, and its toxicity originally was attributed to the presence of large, readily formed Aβ fibrils.
Journal ArticleDOI

Vaccination with soluble Aβ oligomers generates toxicity-neutralizing antibodies

TL;DR: Results support the hypothesis that immunizations of transgenic mice derive therapeutic benefit from the immuno‐neutralization of soluble Aβ‐derived toxins, and suggest analogous immuno-neutralizing of oligomers in humans may be a key in AD vaccines.
Journal ArticleDOI

Amyloid-β peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release

TL;DR: Treatment of rat cortical astrocyte cultures with aggregated Aβ 1–42 peptide induces activation, as assessed by reactive morphological changes and upregulation of selective glial mRNA and proteins, such as the inflammatory cytokine interleukin-1β.